<DOC>
	<DOCNO>NCT02964689</DOCNO>
	<brief_summary>The aim determine recommend phase 2 dose ( RP2D ) binimetinib combination pemetrexed cisplatin , demonstrate combination feasible preliminary activity previously untreated patient advance NSCLC document KRAS mutation .</brief_summary>
	<brief_title>Binimetinib Addition Standard Chemotherapy KRAS Mutated NSCLC .</brief_title>
	<detailed_description>There need effective therapy patient advance NSCLC driven RAS/MEK/ERK pathway . These tumor generally aggressive , almost exclusively non-squamous histology , represent large group patient advance NSCLC harbor specific driver mutation Western population . Based recent preclinical clinical evidence , mitogen-activated protein kinase kinase ( MEK ) -inhibition plus first-line chemotherapy promise new treatment patient NSCLC KRAS [ v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ] mutation . Binimetinib medication without market authorization . Pemetrexed cisplatin marketing authorization Switzerland EU treatment non-small cell lung cancer ( NSCLC ) administer standard backbone treatment accord Swissmedic-approved indication , dose route administration . Binimetinib , pemetrexed cisplatin IMP context phase I trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written inform consent accord Swiss HRA ICHGCP regulation registration prior trialspecific procedure . Histologically cytologically confirm diagnosis NSCLC , predominantly nonsquamous subtype ( adenocarcinoma , large cell carcinoma , NOS ) . Locally advanced metastatic stage IIIIV disease accord 7th TNM classification , ineligible curative treatment . Presence KRAS exon 2 3 ( codon 12 , 13 61 ) mutation local testing ( concomitant EGFR ALK mutation exclude ) . CT scan show measurable disease , define least one lesion measure least one dimension ( nonnodal lesion ≥10 mm long diameter , lymph node ≥15 mm short axis ) accord RECIST 1.1 . Eligible cisplatinbased chemotherapy able take oral medication . WHO performance status 01 . Age 18 75 year . Adequate hematological value : hemoglobin ≥ 90 g/L , ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L . Adequate hepatic function : total bilirubin ≤ 1.5 x ULN &lt; 34.2 μmol/L ; ALT alkaline phosphatase ≤ 2.5 x ULN . Adequate renal function : calculated creatinine clearance ≥ 60 mL/min , accord formula CockcroftGault . Adequate cardiac function : leave ventricular ejection fraction ( LVEF ) ≥ 50 % determined echocardiogram ; QTcF interval must ≤ 480 ms. Women childbearing potential use effective contraception , pregnant lactating agree become pregnant trial treatment 6 month thereafter . A negative serum pregnancy test inclusion trial require woman childbearing potential . Men agree father child trial treatment 6 month thereafter . NSCLC additional small cell carcinoma ( SCLC ) component local diagnostic pathology report . Meningeosis carcinomatosa , symptomatic untreated central nervous system ( CNS ) metastasis . Patients treat , control CNS metastasis enrol 2 week end radiotherapy asymptomatic ( residual neurologic deficit ) long corticosteroid . Previous concurrent malignancy follow exception : adequately treat basal cell squamous cell carcinoma skin ( adequate wound healing require prior registration ) , situ carcinoma cervix , treat curatively without evidence recurrence least 5 year prior registration , superficial bladder cancer , prostate intraepithelial neoplasm , noninvasive indolent malignancy , solid tumor treat curatively without evidence recurrence least 5 year prior registration . Leptomeningeal disease . Concurrent radiotherapy ( patient prior radiotherapy brain metastasis ≥ 7 day prior registration enrol ) . Previous systemic therapy advance NSCLC ; previous adjuvant neoadjuvant chemotherapy allow last dose administer least 6 month ago . Major surgery within 3 week registration . Concurrent treatment experimental drug anticancer therapy . Impaired cardiovascular function clinically severe uncontrolled cardiovascular disease , include follow : congestive heart failure NYHA III IV , history acute coronary syndrome ( include myocardial infarction , unstable angina , coronary artery bypass grafting , coronary angioplasty , stenting ) &lt; 6 month prior registration , symptomatic chronic heart failure ( G2 high ) , history current evidence clinically significant cardiac arrhythmia require medication and/or conduction abnormality &lt; 6 month prior registration except atrial fibrillation paroxysmal supraventricular tachycardia . Uncontrolled arterial hypertension define persistent elevation systolic blood pressure ≥ 150 mmHg diastolic blood pressure ≥ 100 mmHg despite medical treatment . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) ; history retinal degenerative disease . History Gilbert 's syndrome . Neuromuscular disorder associate elevated creatine phosphokinase ( CPK ; e.g . inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) . Neuropathy ( &gt; G1 ) hear impairment/ tinnitus ( &gt; G1 ) . Impairment gastrointestinal function gastrointestinal disease ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . History thromboembolic cerebrovascular event within 6 month prior registration , include transient ischemic attack , cerebrovascular accident , deep vein thrombosis pulmonary embolus . Known history acute chronic pancreatitis . History chronic inflammatory bowel disease Crohn 's disease require medical intervention ( immunomodulatory immunosuppressive medication surgery ) within 12 month prior registration . Known positive serology HIV ( human immunodeficiency virus ) , active hepatitis B , and/or active hepatitis C infection . Active infection within 14 day prior registration . Planning embark new strenuous exercise regimen first dose binimetinib ( NB : muscular activity , strenuous exercise , result significant increase plasma CPK level avoid binimetinib treatment ) . Known lactose intolerance . Known hypersensitivity trial drug hypersensitivity component trial treatment , include premedication . Any concomitant drug contraindicate use pemetrexed cisplatin accord Swissmedicapproved current product information binimetinib accord late version Investigator 's Brochure . Any serious underlying medical , psychiatric , psychological , familial geographical condition , judgment investigator may interfere plan staging , treatment followup , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced non-small cell lung cancer</keyword>
	<keyword>KRAS mutation</keyword>
	<keyword>Binimetinib</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Phase IB trial</keyword>
</DOC>